Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Common Equity (2016 - 2026)

Biomerica's Common Equity history spans 16 years, with the latest figure at $3.3 million for Q1 2026.

  • Quarterly results put Common Equity at $3.3 million for Q1 2026, down 40.06% from a year ago — trailing twelve months through Feb 2026 was $3.3 million (down 40.06% YoY), and the annual figure for FY2025 was $4.1 million, down 37.72%.
  • Common Equity for Q1 2026 was $3.3 million at Biomerica, down from $4.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $11.7 million in Q2 2023 to a low of $3.3 million in Q1 2026.
  • The 5-year median for Common Equity is $6.6 million (2024), against an average of $7.0 million.
  • The sharpest move saw Common Equity soared 40.83% in 2023, then plummeted 50.35% in 2024.
  • Year by year, Common Equity stood at $7.2 million in 2022, then grew by 29.53% to $9.4 million in 2023, then tumbled by 45.5% to $5.1 million in 2024, then decreased by 13.28% to $4.4 million in 2025, then decreased by 25.21% to $3.3 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $3.3 million, $4.4 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.